TRMT6 and hepatocellular carcinoma: For instance, a recent study demonstrated that hepatocellular carcinoma exhibits abnormally elevated levels of m1A, which is associated with a poor prognosis for patients, while TRMT6/TRMT61A is the main enzyme mediating this aberrant m1A modification, m1A56 modification of tRNAAla-AGC and tRNAGlu-CTC promotes the translation of Peroxisome Proliferator Activated Receptor Gamma (PPARδ) and thus enhances the lipid metabolism of hepatocellular carcinoma cells and thus promoting the progression of hepatocellular carcinoma [56].